Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces in Cystic Fibrosis.
作者信息
Morgan Sarah J, Nichols David P, Ni Windy, Hong Gina, Salipante Stephen J, Solomon George M, Rowe Steven M, Clancy John P, Cramer Robert A, Singh Pradeep K
机构信息
Departments of Microbiology and Medicine, University of Washington, Seattle, Washington, USA.
Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
出版信息
Am J Respir Crit Care Med. 2024 Nov 1;210(9):1155-1158. doi: 10.1164/rccm.202406-1128RL.
Abstract
摘要
相似文献
1
Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces in Cystic Fibrosis.
Am J Respir Crit Care Med. 2024 Nov 1;210(9):1155-1158. doi: 10.1164/rccm.202406-1128RL.
2
Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.
Front Pharmacol. 2023 May 9;14:1176815. doi: 10.3389/fphar.2023.1176815. eCollection 2023.
3
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Lancet Respir Med. 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2.
4
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
5
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
6
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
7
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.
Lancet Respir Med. 2024 Nov;12(11):888-900. doi: 10.1016/S2213-2600(24)00208-X. Epub 2024 Aug 13.
8
Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.
Am J Otolaryngol. 2024 May-Jun;45(3):104236. doi: 10.1016/j.amjoto.2024.104236. Epub 2024 Feb 24.
9
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.
10
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
引用本文的文献
1
Deleterious effect of on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cells.
ERJ Open Res. 2025 May 27;11(3). doi: 10.1183/23120541.00970-2024. eCollection 2025 May.
2
Epidemiology, antifungal susceptibility and biological characteristics of clinical Aspergillus fumigatus in a tertiary hospital.
Sci Rep. 2025 May 15;15(1):16906. doi: 10.1038/s41598-025-00187-z.
3
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators.
Mol Cell Pediatr. 2025 May 5;12(1):6. doi: 10.1186/s40348-025-00194-0.
4
The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota.
Microbiology (Reading). 2025 Apr;171(4). doi: 10.1099/mic.0.001553.
5
Recent developments in research: diversity, drugs, and disease.
Microbiol Mol Biol Rev. 2025 Mar 27;89(1):e0001123. doi: 10.1128/mmbr.00011-23. Epub 2025 Feb 10.
6
Confronting the Fungus among Us in the Airways of People with Cystic Fibrosis.
Ann Am Thorac Soc. 2025 Feb;22(2):183-184. doi: 10.1513/AnnalsATS.202411-1229ED.
7
Influence of Fungal Colonization on Exacerbations in Patients with Cystic Fibrosis.
J Fungi (Basel). 2024 Dec 17;10(12):875. doi: 10.3390/jof10120875.
8
The Real-World Effectiveness of Antifungals in People with Cystic Fibrosis and -Positive Cultures.
Ann Am Thorac Soc. 2025 Feb;22(2):193-199. doi: 10.1513/AnnalsATS.202312-1070OC.
本文引用的文献
1
The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of biofilms.
mBio. 2023 Oct 31;14(5):e0151623. doi: 10.1128/mbio.01516-23. Epub 2023 Oct 13.
2
Infection, Allergy, and Inflammation: The Role of in Cystic Fibrosis.
Microorganisms. 2023 Aug 5;11(8):2013. doi: 10.3390/microorganisms11082013.
3
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
Eur Respir J. 2023 Aug 3;62(2). doi: 10.1183/13993003.02153-2022. Print 2023 Aug.
4
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.
J Clin Invest. 2023 May 15;133(10):e167957. doi: 10.1172/JCI167957.
5
Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights.
J Cyst Fibros. 2022 Nov;21(6):1084-1085. doi: 10.1016/j.jcf.2022.09.007. Epub 2022 Sep 21.
6
in the cystic fibrosis lung: pros and cons of azole therapy.
Infect Drug Resist. 2016 Sep 20;9:229-238. doi: 10.2147/IDR.S63621. eCollection 2016.
7
Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center.
Med Mycol. 2016 Nov 1;54(8):781-6. doi: 10.1093/mmy/myw035. Epub 2016 Jun 30.
8
Rapid and specific detection of section Fumigati and Aspergillus fumigatus in human samples using a new multiplex real-time PCR.
Diagn Microbiol Infect Dis. 2014 Oct;80(2):111-8. doi: 10.1016/j.diagmicrobio.2014.06.003. Epub 2014 Jun 19.
Zotero 插件